Your browser doesn't support javascript.
loading
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
Azim, Hatem A; Niman, Samuel M; Partridge, Ann H; Demeestere, Isabelle; Ruggeri, Monica; Colleoni, Marco; Saura, Cristina; Shimizu, Chikako; Saetersdal, Anna B; Kroep, Judith R; Mailliez, Audrey; Warner, Ellen; Borges, Virginia F; Amant, Frédéric; Gombos, Andrea; Kataoka, Akemi; Rousset-Jablonski, Christine; Borstnar, Simona; Takei, Junko; Lee, Jeong Eon; Walshe, Janice M; Ruíz-Borrego, Manuel; Moore, Halle C F; Saunders, Christobel; Bjelic-Radisic, Vesna; Susnjar, Snezana; Cardoso, Fatima; Klar, Natalie J; Spanic, Tanja; Ruddy, Kathryn; Piccart, Martine; Korde, Larissa A; Goldhirsch, Aron; Gelber, Richard D; Pagani, Olivia; Peccatori, Fedro A.
Affiliation
  • Azim HA; Cairo Cure Oncology Center, Cairo, Egypt.
  • Niman SM; Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.
  • Partridge AH; International Breast Cancer Study Group Statistical Center, Boston, MA.
  • Demeestere I; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.
  • Ruggeri M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Colleoni M; Harvard Medical School, Boston, MA.
  • Saura C; Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Shimizu C; Gynecology and Obstetrics Department, Fertility Clinic, HUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Saetersdal AB; Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland.
  • Kroep JR; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Mailliez A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Warner E; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Borges VF; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Amant F; Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
  • Gombos A; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • Kataoka A; Dutch Breast Cancer Research Group (BOOG), Amsterdam, the Netherlands.
  • Rousset-Jablonski C; Breast Cancer Unit, Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Borstnar S; Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada.
  • Takei J; Canadian Clinical Trials Group (CCTG), Toronto, ON, Canada.
  • Lee JE; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO.
  • Walshe JM; Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium.
  • Ruíz-Borrego M; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium.
  • Moore HCF; Antoni van Leeuwenhoek-Netherlands Gynecologic Oncology Cancer Institute, Amsterdam, the Netherlands.
  • Saunders C; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.
  • Bjelic-Radisic V; Breast Oncology Cancer, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Susnjar S; Department of Surgery, Leon Berard Cancer Centre, Centre Léon Bérard, Lyon, France.
  • Cardoso F; Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia.
  • Klar NJ; St Luke's International Hospital, Breast Center, Tokyo, Japan.
  • Spanic T; Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Ruddy K; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.
  • Piccart M; Cancer Trials Ireland, Dublin, Ireland.
  • Korde LA; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
  • Goldhirsch A; Tallaght University Hospital, Dublin, Ireland.
  • Gelber RD; GEICAM Spanish Breast Cancer Group, Madrid, Spain.
  • Pagani O; Hospital Virgen del Rocio Sevilla, Sevilla, Spain.
  • Peccatori FA; Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
J Clin Oncol ; 42(23): 2822-2832, 2024 Aug 10.
Article in En | MEDLINE | ID: mdl-38810178
ABSTRACT

PURPOSE:

We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy. PATIENTS AND

METHODS:

POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months.

RESULTS:

Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5).

CONCLUSION:

In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Reproductive Techniques, Assisted / Fertility Preservation Limits: Adult / Female / Humans / Middle aged / Pregnancy Language: En Journal: J Clin Oncol Year: 2024 Type: Article Affiliation country: Egypt

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Reproductive Techniques, Assisted / Fertility Preservation Limits: Adult / Female / Humans / Middle aged / Pregnancy Language: En Journal: J Clin Oncol Year: 2024 Type: Article Affiliation country: Egypt